Document:

EX-10.37

   

   

  Exhibit 10.37

   

   

  105 W. First Street Owner, L.L.C. c/o Breakthrough Spaces, L.L.C. Tishman Speyer

  45 Rockefeller Plaza New York, New York 10111

   

  January 6, 2022

   

  CRISPR Therapeutics, Inc. 610 Main Street North

  Cambridge, Massachusetts 02139

  Attn: Brendan Smith, Chief Financial Officer

   

  RE:	Lease (the “Lease”) dated as of July 24, 2020, between 105 W. First Street Owner, L.L.C. (the “Landlord”) and CRISPR Therapeutics, Inc. (the “Tenant”)

   

  Ladies and Gentlemen:

   

  Reference is hereby made to the Lease. All capitalized words and phrases used in this letter agreement and not otherwise defined herein shall have the meanings ascribed to them in  the Lease. The purpose of this letter agreement is to memorialize the agreement between Landlord and Tenant concerning the occurrence of certain delays in and adjustments to schedule for the performance of the Base Building Work and the Landlord’s Work, including the Scheduled Commencement Date and the Outside Delivery Date.

   

  On or about June 10, 2021, as part of the plan review and approval process, Tenant submitted certain comments on and requested changes to the Construction Set Plans for the Landlord’s Work (collectively, the “Requested Changes”), which Requested Changes ultimately resulted in the issuance by the Architect of Construction Bulletins Nos. 3 and 4 and  the issuance by the Contractor of Change Request No. 2 (“CR002”). CR002 indicates a delay of twenty-four (24) days in Substantial Completion resulting from the Requested Changes (the “Requested Changes Delays”).

   

  In the spirit of their cooperative relationship and in the interest of compromise, Landlord and Tenant have agreed to enter this letter agreement.

   

  NOW, THEREFORE, for $10.00 and other good and valuable consideration, the receipt, sufficiency and delivery of which are acknowledged, Landlord and Tenant hereby agree, notwithstanding any provisions in the Lease to the contrary, as follows:

   

  1.The Scheduled Commencement Date is hereby extended on a day-for-day basis  by the number of days of Requested Changes Delays (i.e., by twenty-four (24) days) from March 1, 2022 to March 24, 2022.

   

  

   

   

   

  CRISPR Therapeutics, Inc.

  January 6, 2021

  Page 2

   

  2.The Outside Delivery Date is hereby extended on a day-for-day basis by one-half (1/2) of the number of days of Requested Changes Delays (i.e., by twelve (12) days) from April 1, 2022 to April 12, 2022.

   

  3.The two hundred forty (240) day period used to calculate the Rent Commencement Date is hereby reduced on a day-for-day basis by one-half (1/2) of the number  of days of Requested Changes Delays (i.e., by twelve (12) days) to two hundred twenty-eight

  (228) days; except that, if the Commencement Date shall occur on or before March 24, 2022, then the two hundred forty (240) day period used to calculate the Rent Commencement Date shall be reduced by one half (1/2) of the number of days after March 1, 2022 that the Commencement Date occurs (provided that in no event will the Rent Commencement Date occur prior to November 1, 2022).

   

  4.Landlord hereby confirms that as of the date of this letter agreement, no Tenant Delays have occurred, and any additional delays (i.e., other than the Requested Changes Delays) arising from, relating to or otherwise in connection with any other actions or requests by or on behalf of Tenant on or before the date of this letter agreement will not constitute Tenant Delays.

   

  5.Landlord hereby confirms that as of the date of this letter agreement, to its knowledge, no Unavoidable Delays or COVID-19 Delays have occurred or are currently pending that would delay the Commencement Date. Nothing contained herein shall modify, limit, or detract from the provisions of the Lease concerning Unavoidable Delays and/or COVID-19 Delays which Landlord becomes aware of after the date of this letter agreement.

   

  6.Landlord and Tenant will continue to work together cooperatively to assess and reduce the number of days of delay in Substantial Completion, including, without limitation, delays arising out of or resulting from the Requested Changes and CR002.

   

  7.The inspections by ISD of the Base Building Work and the Landlord’s Work shall occur as joint inspections and shall take place concurrently. Accordingly, the seventh (7th) sentence of Section 4.1 of the Lease (which begins with the phrase “The Base Building Work Certificate of Substantial Completion shall include...”) is hereby deleted in the entirety and the definition of Substantial Completion set forth in Section 4.2(r) of the Lease shall be amended to provide that the Base Building Work Certificate of Substantial Completion shall include confirmation of the completion of required inspections of the Base Building Work by ISD.

   

  8.Nothing contained herein constitutes a waiver or release of any other breaches, defaults, or claims under the Lease. Except as expressly and specifically set forth herein, the Lease remains unmodified and in full force and effect, in accordance with and subject to the terms and conditions thereof.

   

  9.This letter agreement may be executed by electronic signatures, each of which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature. Without limitation, in addition to electronically produced signatures, “electronic signature” shall include electronically scanned and transmitted versions (e.g., via PDF and/or DocuSign) of an original signature.  This letter agreement may be executed

   

   

  

   

   

   

  CRISPR Therapeutics, Inc.

  January 6, 2021

  Page 2

   

  in multiple counterparts (which counterparts may be executed and delivered by PDF, DocuSign, or another file sent by email) which shall together constitute a single document. Any executed counterpart of this letter agreement delivered by PDF, DocuSign or another file sent by email shall be equally effective as an original counterpart for all purposes. Notwithstanding any provision contained in the Lease and/or this letter agreement to the contrary, the liability of Landlord for its obligations under this Lease shall be limited to the interests of Landlord in the Real Property (including insurance awards, condemnation proceeds, and undistributed rents arising from the Real Property). In no event shall any partner, member, manager, shareholder, director, officer, principal, employee, agent, or owner of Landlord, direct or indirect, disclosed or undisclosed, be personally liable for any debts, liabilities or obligations of Landlord, or for any claims against Landlord, arising out of or resulting from the Lease and/or this letter agreement. Any such debts, obligations, liabilities or claims shall be satisfied solely out of the interests of Landlord in the Real Property (including insurance awards, condemnation proceeds, and undistributed rents arising from the Real Property). In no event shall any personal judgment be sought or obtained against any partner, member, manager, shareholder, director, officer, principal, employee, agent, or owner of Landlord, direct or indirect, disclosed or undisclosed.  The submission of drafts of this document for examination and negotiation does not constitute an offer, or the acceptance of an offer, and this letter agreement shall not be binding upon Landlord or Tenant unless and until Landlord shall have executed and delivered a fully executed copy of this letter agreement to Tenant.

   

  In order to confirm our agreement with the terms of this letter agreement, we would appreciate your signing this letter below and returning a copy to me.

   

  [Signatures continued on following page]

   

   

  

   

   

   

  CRISPR Therapeutics, Inc.

  January 6, 2021

  Page 2

   

  IN WITNESS WHEREOF, Landlord and Tenant have executed this letter agreement as of the day and year first above written.

  LANDLORD:

   

  105 W FIRST STREET OWNER, L.L.C.,

  a Delaware limited liability company

   

  By:	/s/ Daniel Belldegrun	

   Name: Daniel Belldegrun

      Its: President and Chief Executive Officer

  TENANT:

   

  CRISPR THERAPEUTICS, INC.,

  a Delaware corporation

   

  By:	/s/ Brendan Smith	 

  	Name: Brendan Smith

  	Its: CFO

   

  The foregoing letter agreement is hereby consented to:

   

  GUARANTOR:

   

  CRISPR THERAPEUTICS AG, a Swiss corporation

  By:	/s/ Samarth Kulkarni	 

       Name: Samarth Kulkarni

       Its: CEOvkin_ex101.htm

EXHIBIT 10.1
  
 SECURITIES PURCHASE AGREEMENT
  
 This Securities Purchase Agreement (this “Agreement”) is made and entered into as of February 9, 2022, by and between Viking Energy Group, Inc., a Nevada corporation (the “Buyer”) and Jedda Holdings LLC, a Wyoming limited liability company (the “Seller”). 
  
 This Agreement sets forth the terms and conditions upon which the Seller is selling to the Buyer and the Buyer is purchasing from the Seller fifty-one Common Units of Viking Protection Systems, LLC, a Nevada limited liability company (the “Company”), constituting 51% of the membership interests of the Company (hereinafter referred to as the “Units”).
  
 In consideration of the mutual agreements contained herein, the parties hereby agree as follows:
  
 I. SALE OF THE UNITS
  
 1.01 Units being Sold. Subject to the terms and conditions of this Agreement, the Seller agrees to sell the Units to the Buyer. 
  
 1.02 Purchase Price. As consideration for the Units, the Buyer agrees to issue to the Seller, shares of Convertible Preferred Stock of the Buyer with a face value of $10,000 per share (the “Preferred Shares”), or pay cash to the Seller, if applicable, as follows:
  
 	  
	 a. 
	 475 Preferred Shares will be issued to the Seller on closing, and such shares will be convertible into shares of common stock of the Buyer (“Viking Common Stock”) based on a conversion price of $0.60 per share:

	  
	  
	  

	  
	 b. 
	 upon the sale of ten thousand units of the electric transmission ground fault prevention trip signal engaging system (the “System”), the Buyer shall, at the option of the Seller (i) pay the Seller $1,000,000 in cash; or (ii) issue to the Seller 100 Preferred Shares convertible into Viking Common Stock based on a conversion price of $0.75 per share;

	  
	  
	  

	  
	 c.
	 upon the sale of twenty thousand units of the System, the Buyer shall, at the option of the Seller (i) pay the Seller $2,000,000 in cash; or (ii) issue to the Seller 200 Preferred Shares convertible into Viking Common Stock based on a conversion price of $1.00 per share;

	  
	  
	  

	  
	 d.
	 upon the sale of thirty thousand units of the System, the Buyer shall, at the option of the Seller (i) pay the Seller $3,000,000 in cash; or (ii) issue to the Seller 300 Preferred Shares convertible into Viking Common Stock based on a conversion price of $1.25 per share;

	  
	  
	  

	  
	 e.
	 upon the sale of fifty thousand units of the System, the Buyer shall, at the option of the Seller (i) pay the Seller $4,000,000 in cash; or (ii) issue to the Seller 400 Preferred Shares convertible into Viking Common Stock based on a conversion price of $1.50 per share; and

	  
	  
	  

	  
	 f.
	 upon the sale of one hundred thousand units of the System, the Buyer shall, at the option of the Seller (i) pay the Seller $6,000,000 in cash; or (ii) issue to the Seller 600 Preferred Shares convertible into Viking Common Stock based on a conversion price of $2.00 per share.

  
 	 
	-1-
	

	 

   
 Notwithstanding the above, the Buyer shall not effect any conversion of a Preferred Shares, and the Seller shall not have the right to convert any Preferred Shares, to the extent that after giving effect to the conversion, the Seller (together with the Seller’s affiliates, and any persons acting as a group together with the Seller or any of the Seller’s affiliates) would beneficially own in excess of 4.99% of the number of shares of the Viking Common Stock outstanding immediately after giving effect to the issuance of shares of Viking Common Stock issuable upon conversion of the Preferred Share(s) by the Seller. The Seller, upon not less than 61 days’ prior notice to the Buyer, may increase or decrease the beneficial ownership limitation provisions of this Section, provided that the beneficial ownership limitation in no event exceeds 9.99% of the number of shares of Viking Common Stock outstanding immediately after giving effect to the issuance of shares of Viking Common Stock upon conversion of the Preferred Share(s) held by the Seller and the beneficial ownership limitation provisions of this Section shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Buyer.
  
 1.03 Closing. The Closing of the transactions shall take place on February 9, 2022, or at such other date and time as the parties may mutually agree in writing.
  
 1.04 Delivery by the Seller. At the Closing, the Seller shall deliver the Units to the Buyer as directed by the Buyer.
  
 II. RELATED TRANSACTIONS
  
 2.01 Finders. The Seller and the Buyer acknowledge, respectively, that there were no finders with respect to the transaction contemplated herein that either is obligated to. 
  
 2.02 Other Buyers. The Seller acknowledges that it has not solicited any other buyer to purchase Units of the Company besides the Buyer. The Seller further acknowledges that there has been no influence exerted over the Seller by any officer or director of the Company regarding the sale of Seller’s Units. 
  
 III. REPRESENTATIONS AND WARRANTIES OF SELLER
  
 The Seller hereby represents and warrants as follows:
  
 3.01 Authority; No Violation. The execution and delivery of this Agreement by the Seller, and the consummation of the transactions contemplated hereby have been duly authorized. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will constitute a violation or default under any term or provision of any contract, commitment, indenture, other agreement or restriction of any kind or character to which the Seller is a party or by which the Seller is bound. 
  
 	 
	 -2-

	

	 

  
 3.02 Disclosure. No representation or warranty by the Seller contained in this Agreement, and no statement contained in any instrument, list, certificate, or writing furnished to the Buyer pursuant to the provisions hereof or in connection with the transaction contemplated hereby, contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading or necessary in order to provide a prospective purchaser of the business of the Company with proper information as to the Company and its affairs.
  
 IV. REPRESENTATIONS AND WARRANTIES BY BUYER
  
 Buyer hereby represents and warrant as follows:
  
 4.01 Authority; No Violation. The execution and delivery of this Agreement by the Buyer and the consummation of the transactions contemplated hereby by Buyer has been duly authorized. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will constitute a violation or default under any term or provision of any contract, commitment, indenture, other agreement or restriction of any kind or character to which any of the individual Buyer is a party or by which any of the individual Buyer is bound.
  
 4.02 Representations Regarding the Acquisition of the Units.
  
 (a) The Buyer understands the speculative nature and the risks of investments associated with the Company and confirms that it is able to bear the risk of the investment;
  
 (b) The Buyer has had the opportunity to ask questions of the Seller and receive additional information about the Company, or could acquire it without unreasonable effort or expense necessary to evaluate the merits and risks of any such purchase. Further, the Buyer has been given an opportunity to question the Seller and receive related documentation to the purchase;
  
 (c) The Buyer has sufficient knowledge and experience in financial and business matters, and is sufficiently familiar with investments of the type represented by the Units, including familiarity with previous private and public purchases of speculative and restricted securities, that it is capable of evaluating the merits and risks associated with purchase of the Units; and
  
 (d) In evaluating the merits of the purchase of the Units, Buyer has relied solely on his, her or its own investigation concerning the Company and has not relied upon any representations provided by the Seller. 
  
 	 
	-3-
	

	 

   
  V. SURVIVAL OF REPRESENTATIONS
  
 5.01 Survival of Representations. All representations, warranties, and agreements made by any party in this Agreement or pursuant hereto shall survive the execution and delivery hereof and any investigation at any time made by or on behalf of any party.
  
 VI. ADDITIONAL CONDITIONS TO CLOSING
  
 6.01 Obligation of Buyer to Close. The Buyer shall not be obligated to close this transaction unless it is satisfied, following reasonable investigation, that all of the representations of Seller as of the date of execution of this Agreement and as of the date of Closing under this Agreement are true and correct in all material respects. 
  
 6.02 Obligation of Seller to Close. The Seller shall not be obligated to close this transaction unless it is satisfied, following reasonable investigation, that all of the representations of the Buyer as of the date of execution of this Agreement and as of the date of Closing under this Agreement are true and correct in all material respects.
  
 VII. INDEMNIFICATION
  
 7.01 [Intentionally deleted]. 
  
 VIII. MISCELLANEOUS
  
 8.01 Expenses. Each of the parties shall bear its own expenses incurred in conjunction with the Closing hereunder.
  
 8.02 Further Assurances. From time to time, at the request of the Buyer and without further consideration, the Seller shall execute and transfer such documents and take such action as the Buyer may reasonably request in order to effectively consummate the transactions herein contemplated.
  
 8.03 Parties in Interest. All the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by the heirs, beneficiaries, representatives, successors, and assigns of the parties hereto.
  
 8.04 Prior Agreements; Amendments. This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. This Agreement may be amended only by a written instrument duly executed by the parties hereto or their respective successors or assigns.
  
 8.05 Headings. The section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretations of this Agreement.
   
 	 
	-4-
	

	 

   
 8.06 Confidentiality. Each party hereby agrees that all information provided by the other party and identified as “confidential” will be treated as such, and the receiving party shall not make any use of such information other than with respect to this Agreement. If the Agreement shall be terminated, each party shall return to the other all such confidential information in their possession, or will certify to the other party that all of such confidential information that has not been returned has been destroyed.
  
 8.07 Notices. All notices, requests, demands, and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered or mailed (registered or certified mail, postage prepaid, return receipt requested) to the parties at their address specified on the signature page hereto, with a copy sent as indicated on the signature page.
  
 8.08 Counterparts. This Agreement may be executed simultaneously in several counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
  
 8.09 Applicable Law. This Agreement shall be governed by, and construed in accordance with the laws of the State of Nevada in respect of contracts, and the State of Nevada, in respect of matters of a corporate nature.
  
 	 
	-5-
	

	 

  
 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered on the date first above written.
  
  
 	 	BUYER:	
	  
	  
	  

	  
	 Viking Energy Group, Inc.
	  

	 	 	 	 
		By:	/s/ James A. Doris	
	  
	  
	Name: James A. Doris	 
	 	 	Title: Chief Executive Officer	 
	 	 	 	 
	  
	 SELLER:
	  

	  
	  
	  
	  

	  
	 Jedda Holdings LLC
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Curt Bernhardt
	  

	  
	  
	 Name: Curt Bernhardt
	  

	  
	  
	 Title: Manager
	  

  
 	 
	-6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]